Johnathan Baines, MD
Family Medicine · Ruston, LANPI 1679769889
Payments from drug & device makers
Across 229 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$619
- Bayer$599
- Lilly USA, LLC$433
- Amgen$375
- Boehringer Ingelheim$238
- Corcept Therapeutics$197
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,63498%
- Education$732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $619 |
| Bayer | 39 | $599 |
| Lilly USA, LLC | 30 | $433 |
| Amgen | 22 | $375 |
| Boehringer Ingelheim | 16 | $238 |
| Corcept Therapeutics | 8 | $197 |
| AstraZeneca | 11 | $168 |
| AbbVie | 6 | $147 |
| Kowa Pharmaceuticals America, Inc. | 6 | $115 |
| Pfizer | 6 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $68 |
| Merck | 5 | $68 |
| Abbott | 3 | $59 |
| Nevro Corp. | 3 | $55 |
| Exact Sciences | 3 | $54 |
| GSK | 3 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Insulet Corporation | 1 | $26 |
| Mylan Specialty L.p. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Inogen, Inc. | 1 | $20 |
| Abiomed | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
How this compares
$3,707 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 125 | $143,056 |
| KerendiaFinerenone | 95 | $102,193 |
| OzempicSemaglutide | 83 | $101,327 |
| JardianceEmpagliflozin | 104 | $90,513 |
| FarxigaDapagliflozin Propanediol | 99 | $80,452 |
| EliquisApixaban | 131 | $64,625 |
| XeljanzTofacitinib Citrate | 21 | $50,993 |
| LinzessLinaclotide | 55 | $35,862 |
| JanuviaSitagliptin Phosphate | 35 | $29,075 |
| TradjentaLinagliptin | 26 | $18,542 |
| UbrelvyUbrogepant | 11 | $17,152 |
| XareltoRivaroxaban | 20 | $16,851 |
| VraylarCariprazine Hcl | 11 | $15,811 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $15,277 |
| TrulicityDulaglutide | 18 | $14,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $433 | $157,164143 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Stiolto Respimat | $238 | $131,172156 claims |
| PfizerEliquis, Xeljanz | $100 | $115,618152 claims |
| BayerKerendia | $599 | $102,19395 claims |
| Novo NordiskOzempic | $619 | $101,32783 claims |
| AstraZenecaFarxiga, Brilinta | $168 | $85,333110 claims |
| AbbVieLinzess, Ubrelvy, Vraylar | $147 | $68,82577 claims |
| MerckJanuvia | $68 | $29,07535 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $30 | $11,32025 claims |
| GSKBreo Ellipta | $50 | $10,76024 claims |
| NovartisEntresto | $20 | $9,73328 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $2,30830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Ruston
- William SandersRuston$16K
- Michael PhillipsRuston$16K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.